AGS Health(R) CEO Patrice Wolfe Named one of the Becker's Healthcare 'Top Women to Know in Health IT'
WASHINGTON, DC / ACCESS Newswire AGS Health ® CEO Patrice Wolfe has been named to the Becker's Hospital Review list of 'Women in Health IT to Know' in 2025. The annual list recognizes women who are harnessing the power of health IT to help shape the future of the healthcare industry.
Wolfe has been at the helm of AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers across the U.S., for nearly six years. During her tenure, the company has evolved into a market leader in technology-led RCM solutions, strengthening its capabilities through strategic acquisitions and the organic development of proprietary technologies.
Central to Wolfe's leadership is a bold vision for a frictionless revenue cycle powered by a hybrid intelligence model that seamlessly blends human expertise with the speed, scale, and precision of artificial intelligence (AI). This model enhances human decision-making with AI's analytical power, creating a synergistic system designed to prioritize outcomes over narrowly defined metrics and point solutions.
'Healthcare leaders are seeking a more strategic approach to revenue cycle management-one that goes beyond transactional efficiency and focuses on delivering measurable financial and clinical outcomes,' said Wolfe. 'That's the philosophy behind our hybrid intelligence model. Our clients view us not merely as a vendor but as a long-term strategic partner. The success of our solutions is measured by the tangible impact we deliver, whether that's increasing cash flow, reducing denials, or improving the patient financial experience.'
Under Wolfe's leadership, AGS Health has introduced a series of transformative advancements aimed at modernizing and optimizing revenue cycle operations. Key innovations include the deployment of agentic automation, autonomous medical coding solutions, and hybrid intelligence solutions for front-end financial clearance and prior authorization processes. The company has also developed proprietary workflow orchestration tools that enhance the efficiency, accuracy, and decision-making capabilities of its service teams through intelligent automation and real-time data insights.
Wolfe also spearheaded the company's geographic expansion into Mexico and the Philippines, broadening customers' access to diverse, highly skilled talent pools that are uniquely suited for clinical administrative support roles.
In recognition of its strong workplace culture and employee engagement, AGS Health earned Great Place to Work ® certification in India, the United States, and the Philippines. The company also achieved significant industry recognition, including being named a Leader in Everest Group's Medical Coding Operations PEAK Matrix ® Assessment and receiving four consecutive Leader and Star Performer designations in Everest Group's RCM Operations evaluations.
Additional accolades under Wolfe's tenure include being named 'Most Improved Services Solution – Best in KLAS: Software & Services,' earning the KLAS Research and Censinet Cybersecurity Transparent designation, and receiving the UiPath AI25 Award along with the Data Security Council of India (DSCI) Excellence Award for Best Security Practices in an Organization.
'I am honored to be among such an elite group of women who are reshaping the healthcare industry,' says Wolfe. 'But I did not achieve this honor alone; credit extends to the exceptional AGS Health team, which shares my commitment to leveraging the latest technologies to deliver exceptional quality to our healthcare customers.'
The women leaders recognized on Becker's list, curated by the editorial team from nominations submitted across the healthcare ecosystem, utilize technology to drive meaningful change by streamlining administrative processes, enhancing care delivery, standardizing workflows, and elevating overall system efficiency. In its announcement, Becker's Healthcare stated its pride in honoring trailblazing women in health IT for their unwavering commitment to improving healthcare, adding that their leadership and innovation are essential to the continued success of their organizations and the healthcare industry.
The complete list of Women in Health IT to Know can be accessed here.
About AGS Health
AGS Health is more than a revenue cycle management company-we're a strategic partner for growth. Our distinctive methodology blends award-winning services with intelligent automation and high-touch customer support to deliver peak end-to-end revenue cycle performance and an empowering patient financial experience.
We employ a team of 15,000 highly trained and college-educated RCM experts who directly support more than 150 customers spanning a variety of care settings and specialties, including nearly 50% of the 20 most prominent U.S. hospitals and 40% of the nation's 10 largest health systems. Our thoughtfully crafted RCM solutions deliver measurable revenue growth and retention, enabling customers to achieve the revenue to realize their vision.
# # #
Media Contact:
Liz Goar
NPC Creative Services
liz@npccs.com
SOURCE: AGS Health
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
StopTheBleed.com Launches As A Dedicated Resource for Bleeding Control Kits
LELAND, N.C., June 12, 2025 /PRNewswire/ -- In recognition of the 10th anniversary of the STOP THE BLEED® initiative, Rescue Essentials is proud to announce the launch of a streamlined e-commerce destination for officially licensed STOP THE BLEED® kits and mass casualty response solutions. Designed to help organizations of all sizes prepare for bleeding emergencies, provides expertly curated kits for schools, public buildings, factories, offices, and anywhere else traumatic bleeding can happen. Each kit is built at our North Carolina facility with trusted components from Rescue Essentials and other leading manufacturers such as SAM Medical and North American Rescue " makes it easier than ever for people to find the exact bleeding control kits they need, whether to comply with local legislation or simply to be better prepared," said Jim Seidel, Rescue Essentials CEO. "Our team is here to assist with product selection, identify applicable state requirements, and even help customers locate available grant funding to support their preparedness goals." As a licensed partner of the U.S. Department of Defense's STOP THE BLEED® program, Rescue Essentials is committed to supporting this international public health initiative, which empowers bystanders to take action and save lives in the critical moments following a traumatic injury. represents Rescue Essentials' continued dedication to delivering high-quality, accessible medical response products and training support to first responders, safety officials and everyday heroes across the country. About Rescue Essentials Since 2007, Rescue Essentials has remained focused on its original goal — to offer top quality tactical, emergency, combat, and outdoor medical products at affordable prices, delivered in a timely manner. Rescue Essentials' core capabilities include the design, manufacture, and assembly of purpose-built trauma and medical kits for law enforcement, EMS and government agencies. Rescue Essentials, a division of Tri-Tech Forensics, Inc., is based in Leland, N.C. View original content to download multimedia: SOURCE Tri-Tech Forensics
USA Today
2 hours ago
- USA Today
Think Power Solutions Earns Great Place to Work(R) Certification for Fifth Consecutive Year
AI Innovation, Entrepreneurial Culture, M&A Growth, and Operational Excellence Fuel 2025 Recognition Think Power Solutions , a leading provider of AI-enabled utility infrastructure solutions, proudly announces its fifth consecutive Great Place to Work® Certification™ , highlighting its exemplary commitment to fostering a safe, entrepreneurial, and empowering work environment. 'This recognition, for the fifth consecutive year, is especially meaningful because it's based entirely on feedback from our teams,' said Hari Vasudevan, PE, Founder & CEO of Think Power Solutions. 'At Think Power, we believe that when we take care of our people, they care for our customers and investors. As we continue to grow both organically and through targeted acquisitions, we remain focused on driving AI-powered innovation, strengthening customer relationships, and fostering a workplace culture that sets the standard for safety and excellence in the utility industry.' Driving Organic Growth and M&A Strategy As part of its long-term strategy, Think Power Solutions continues to seek partnerships with entrepreneur/family-led firms specializing in utility infrastructure services that drive America's electric utility resilience, reliability, and smarter capital investment. Focus areas include: Advisory services Engineering services Project management Specialized field services Software solutions Through strategic M&A, the company aims to scale nationally, generate operational synergies, and accelerate industry-wide AI innovation to better serve its clients. 'We couldn't be prouder of the positive response we received from our employees. This is a testament to our employee-centric culture that binds us together. We're excited to drive further growth in the utility sector and will continue to improve our workplace culture. Think Power Solutions continues to attract top talent and deliver industry-leading utility infrastructure services,' said David Chandler , CHRO, Think Power Solutions. Think Power fosters a culture where employees are empowered, connected, and driven by purpose. This commitment is reflected in key survey results: nearly 90% of employees express strong pride in their work and believe customers would rate Think Power's service as 'excellent.' These insights reinforce the company's people-first philosophy and reputation for delivering high-performance, client-focused solutions. About Think Power Solutions Think Power Solutions is a leading provider of AI-enabled utility infrastructure solutions. The company partners with many of the nation's largest investor-owned and cooperative utilities. Known for its operational excellence, innovative technology, and industry-leading safety record, Think Power has earned a reputation as a trusted partner in the utility sector. The company actively engages in key industry organizations, including the Edison Electric Institute (EEI), and maintains a strong client-focused approach. With a culture rooted in innovation, excellence, and employee engagement, Think Power continues to attract top-tier talent and deliver solutions that support the evolving needs of the utility industry. Learn more at . Follow us on LinkedIn , Twitter , and Facebook . About Great Place To Work® As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Media Contact: Sayantan Dasgupta Director, Marketing – Brand & Content SOURCE: Think Power Solutions View the original press release on ACCESS Newswire
Yahoo
2 hours ago
- Yahoo
Xediton Pharmaceuticals Inc. ("Xediton") Announced Today the Canadian Approval and Availability of Vabomere(r) (Meropenem-Vaborbactam) in Canada
Oakville, Ontario--(Newsfile Corp. - June 12, 2025) - Xediton Pharmaceuticals Inc. is proud to announce that Vabomere® (meropenem-vaborbactam) has been approved by Health Canada and is now commercially available across the country. Vabomere is indicated in adults for the treatment of complicated urinary tract infections including pyelonephritis, complicated intra-abdominal infection, hospital acquired pneumonia including ventilator associated pneumonia, bacteremia and other infections with limited treatment options known or suspected to be caused by susceptible microorganisms, including KPC-producing CRE—one of the most critical AMR threats identified by Health Canada and the World Health Organization. "The launch of Vabomere® in Canada marks a significant milestone for our company, patients and healthcare practitioners," said George Gafrey, President of Xediton Pharmaceuticals. This therapy provides physicians with a much-needed tool to treat life-threatening infections caused by organisms that are increasingly difficult to manage. We are proud of the collaborative effort by the Melinta and Xediton teams to make the product available, and we are committed to ensuring it reaches those who need it most." "We are thrilled that VABOMERE is now readily accessible to patients in Canada," said Christine Ann Miller, President and Chief Executive Officer at Melinta. We are pleased to be able to partner with Xediton Pharmaceuticals in support of the registration and commercializing of VABOMERE in Canada, continuing to deliver on Melinta's commitment of ensuring that all people who need our life-saving therapies can get them." Vabomere combines meropenem, a trusted broad-spectrum carbapenem, with vaborbactam, a novel β-lactamase inhibitor. The approval is supported by data from TANGO II, a global Phase III clinical trial demonstrating improved clinical cure rates and survival compared to best available therapy in patients with CRE infections. Vabomere reflects Xediton Pharma's commitment to supporting antimicrobial stewardship and advancing therapies that protect patients and preserve the power of antibiotics. About Vabomere® VABOMERE is an antibacterial combination product for intravenous infusion containing meropenem (a trusted carbapenem) and vaborbactam (a novel beta-lactamase inhibitor). VABOMERE is indicated in adults for the treatment of the following infections known or suspected to be caused by carbapenem-resistant, vaborbactam/meropenem-susceptible Gram-negative bacteria: Complicated urinary tract infections (cUTI), including pyelonephritis, Complicated intra-abdominal infection (cIAI), Hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), Bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above, Other infections with limited treatment options. Gram-negative organisms include Enterobacterales, such as Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For further information on VABOMERE, please consult the product monograph available at: About Xediton Pharmaceuticals Inc. Xediton Pharmaceuticals is a specialty pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, CNS, GI, Ophthalmology, Renal and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies. For more information, please visit About Melinta TherapeuticsMelinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. The company focuses its expanding portfolio on serving patients with an unmet need because that's how it makes the most meaningful impact. Melinta Therapeutics' portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, its commitment to patients, and its portfolio of therapies, including their important safety information, visit Contact:George Gafrey, President of Xediton Pharmaceuticals info@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
